title: Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent.
abstract: BACKGROUND
  Marrow damage from chemo- and radiation therapies has been suggested to affect quality and quantity of hematopoietic stem cell (HSC) products. We tested the hypothesis that CD34+ cells (HSCs) from low mobilizers are qualitatively inferior to HSCs from high mobilizers.
  
  
  METHODS
  HSC quality was defined by proportion of primitive HSC subsets (CD34+CD38-, CD34+HLA-DR-, and CD34+ in G0 stage of cell cycle), the proportion of HSCs that express CXCR4 and CD26 homing proteins, and days to neutrophil and platelet (PLT) engraftments after transplant. HSC content and CD34 subsets analyses were performed using flow cytometry following the ISHAGE protocol. We evaluated the HSC quantity and quality of 139 autologous filgrastim-mobilized HSC products. Patients were categorized into low, moderate, and high mobilizers if their total HSC collection was less than 3 × 10(6), 3 × 10(6) or more and less than 5 × 10(6), and 5 × 10(6)/kg or more, respectively.
  
  
  RESULTS
  The median number of primitive CD34 subsets increases with increasing HSC numbers and this association was significant (p = 0.001). However, when the ratios of the primitive CD34 subsets to total HSC counts were compared among the mobilization groups, the ratios were not significantly different. Coexpression of neither CD26 nor CXCR4 with CD34 antigen correlated with HSC mobilization. Evaluation of days to neutrophil engraftment among the mobilization groups did not show a significant difference (p = 0.1). However, days to PLT engraftment among the mobilization groups was significantly different (p = 0.05).
  
  
  CONCLUSIONS
  The quality of HSCs from low mobilizers was comparable to HSCs from high mobilizers.
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic Florida, Jacksonville, Florida 32224, USA.
authors.forename: Liuyan
authors.initials: L
authors.lastname: Jiang
authors.forename: Sunny
authors.initials: S
authors.lastname: Malik
authors.forename: Mark
authors.initials: M
authors.lastname: Litzow
authors.forename: Dennis
authors.initials: D
authors.lastname: Gastineau
authors.forename: Ivana
authors.initials: I
authors.lastname: Micallef
authors.forename: Vivek
authors.initials: V
authors.lastname: Roy
authors.forename: Lawrence
authors.initials: L
authors.lastname: Solberg
authors.forename: Abba C
authors.initials: AC
authors.lastname: Zubair
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D005260:Female; D006085:Graft Survival / Q000502:physiology*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods / Q000592:standards*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000592:standards*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D007937:Leukapheresis / Q000379:methods; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D011446:Prospective Studies; D011786:Quality Control; D014182:Transplantation, Autologous; D055815:Young Adult
chemical_list: D018952:Antigens, CD34